睿昂基因: 睿昂基因第三届监事会第四次会议决议公告

Meeting Overview - The third meeting of the Supervisory Board of Shanghai Ruian Gene Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Financial Reporting - The Supervisory Board approved the 2025 Half-Year Report and its summary, confirming that the report accurately reflects the company's situation without any false statements or omissions [1][2]. - The voting results for this approval were unanimous, with 3 votes in favor, 0 against, and 0 abstentions [2]. Fund Management - The Supervisory Board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the management of these funds complies with relevant regulations and internal policies [2][3]. - The report confirmed that the funds were stored and used in designated accounts, with no violations or misappropriations reported [2]. Profit Distribution - The Supervisory Board approved the profit distribution plan for the first half of 2025, which aligns with legal regulations and the company's profit distribution policy [3]. - This proposal also received unanimous approval, with 3 votes in favor, 0 against, and 0 abstentions [3]. Next Steps - All approved proposals will be submitted to the shareholders' meeting for further deliberation [3].